miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. by Schou, J.V. et al.
miR-345 in Metastatic Colorectal Cancer: A Non-Invasive
Biomarker for Clinical Outcome in Non-KRAS Mutant
Patients Treated with 3rd Line Cetuximab and Irinotecan
Jakob V. Schou1*., Simona Rossi2., Benny V. Jensen1, Dorte L. Nielsen1, Per Pfeiffer3, Estrid Høgdall5,
Mette Yilmaz6, Sabine Tejpar4, Mauro Delorenzi9,8,2, Mogens Kruhøffer7, Julia S. Johansen1
1Department of Oncology, Herlev University Hospital, Herlev, Denmark, 2 Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland,
3Department of Oncology, Odense University Hospital, Odense, Denmark, 4Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium, 5Department of
Pathology, Herlev University Hospital, Herlev, Denmark, 6Department of Oncology, Aalborg University Hospital, Aalborg, Denmark, 7AROS Applied Biotechnology,
Aarhus, Denmark, 8Department of Oncology, University of Lausanne, Lausanne, Switzerland, 9 Ludwig Center for Cancer Research, University of Lausanne, Lausanne,
Switzerland
Abstract
Introduction: MicroRNAs (miRNAs) have important regulatory functions in cellular processes and have shown promising
potential as prognostic markers for disease outcome in patients with cancer. The aim of the present study was to find
miRNA expression profiles in whole blood that were prognostic for overall survival (OS) in patients with metastatic
colorectal cancer (mCRC) treated with cetuximab and irinotecan.
Methods: From 138 patients with mCRC in 3rd line therapy with cetuximab and irinotecan in a prospective phase II study,
738 pretreatment miRNAs were isolated and profiled from whole blood using the TaqMan MicroRNA Array v2.0. Mutation
status of KRAS, BRAF, and PI3KCA was known.
Results: After Bonferroni adjustment, 6 miRNAs: (miR-345, miR-143, miR-34a*, miR-628-5p, miR-886-3p and miR-324-3p),
were found associated with short OS. miR-345 was the strongest prognostic miRNA, significant in the full cohort and in the
non-KRAS mutant population. miR-345, as a continuous variable in the full cohort, resulted in a hazard ratio (HR) of 2.38 per
IQR (CI 95%: 1.8–3.1, P-value = 2.86e207, Bonferroni adjusted, univariable analysis) and a HR= 1.75 per IQR (CI 95%: 1.24–
2.48, P-Wald = 1.45e-03) in the multivariable analysis adjusted for gender, age, KRAS, PI3KCA and performance status. miR-
345 was prognostic in progression-free survival (PFS) with a HR= 1.63 per IQR (CI 95%: 1.25–2.114, P-Wald = 2.92e-4) in the
multivariable analysis. In addition, high miR-345 expression was associated with lack of response to treatment with
cetuximab and irinotecan.
Conclusion: We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single
prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
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Introduction
Colorectal cancer (CRC) is the 3rd most common cancer
worldwide. Twenty percent of the patients diagnosed with CRC
have metastatic disease and an additional 30–35% will develop
metastases later during the course of their disease [1,2].
Cetuximab, an IgG1 monoclonal antibody directed against the
Epidermal Growth Factor Receptor (EGFR), has shown efficacy in
combination with chemotherapy in patients with metastatic
colorectal cancer (mCRC), although not in patients with KRAS
mutations, [3,4] which are seen in about 40% of the patients with
CRC. However, only a subset of patients with KRAS wild type (wt)
will benefit from cetuximab. Thus, there is a great need to identify
new biomarkers of treatment response to cetuximab in the
subgroup of patients with mCRC and KRAS.
During the last few years, there has been a rapidly growing
interest in microRNAs (miRNAs) as potential new biomarkers in
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patients with cancer. MiRNAs are small endogenous non-coding
RNAs with 19–22 nucleotides regulating gene expression at the
posttranscriptional level. To date, more than 2000 human miRNA
sequences have been identified, and the number is growing [5].
MiRNAs have important regulatory functions in basic cellular
processes and act as oncogenes and tumor-suppressor genes [6].
MiRNAs are involved in cancer predisposition, development and
progression through gene deregulation and/or single-nucleotide
polymorphism. MiRNAs in a cancer setting can be classified on
the basis of their main functions: oncomir, metastamir, apoptomir,
hypoxamir and angiomir.
Circulating miRNAs can be easily collected and seem very stable
under harsh conditions, long storage time and after multiple freeze-thaw
cycles.[7,8] In addition, a blood sample is more convenient and less
invasive for patients than a biopsy.
Besides having a diagnostic potential, [9,10,11] certain miRNAs
have been shown to be prognostic. Serum miR-141 was suggested
as a prognostic biomarker for patients with CRC [12] and serum
miR-21 as a diagnostic and prognostic biomarker in CRC.[13] The
aim of the present prospective biomarker study was to evaluate whether profiles
of miRNA in whole blood were prognostic for overall survival and
clinical outcome in patients with mCRC before 3rd line treatment
with cetuximab and irinotecan.
Methods
Patients and Treatment
In a prospective phase II study designed to evaluate the efficacy
of cetuximab and irinotecan as 3rd line therapy in patients with
mCRC, pretreatment whole blood miRNA expressions were
measured in 143 patients. All patients were resistant to 5-FU,
oxaliplatin and irinotecan and treated with irinotecan (180 mg/
m2) and cetuximab (500 mg/m2) every second week [14]. Patients
were included from three Danish Hospitals from October 2006 to
October 2008 and treated until disease progression and followed
until death or September 1, 2012.
Ethics Statement
All patients provided written informed consent, and the study
was approved by the Regional Ethics Committee under the
Danish National Committee on Health Research Ethics (VEK ref.
KA-20060094, www.cvk.sum.dk).
KRAS, BRAF and PI3KCA Mutation Status
From all patients, formalin fixed paraffin embedded (FFPE)
tissue blocks representing the tumor were selected. The FFPE
tissues were cut into 3–4 micrometers sections and stained with
hematoxylin and eosin (H&E) to evaluate and confirm tumor
tissue in the selected tissue block. Briefly, three tissue sections were
treated once with xylene, followed with one wash in Ethanol. The
pellet was re-suspended in ATL (tissue lysis buffer) buffer and
treated with Proteinase-K overnight at 56uC. After inactivation of
Proteinase-K by heating the DNA was extracted using the
QIAamp DNA Mini Kit.
KRAS mutations in codon 12 and 13 were analyzed using the
TheraScreen KRAS mutation kit (DxS Ltd, Manchester, United
Kingdom) which identify 7 somatic KRAS mutations. The patients
were classified according to whether a mutation was present (KRAS
mutant, mt) or not (KRAS wild type, wt).[15,16] V600 BRAF
mutation analyses with a sensitivity of 5% were performed by
pyrosequencing (Pyromark Q24) using primers as described by
Richman et al [17]. PIK3CA mutations were detected using the
TheraScreen PI3KCA mutation kit (DXS diagnostics), testing for
four somatic mutations in exon 9 and in exon 20 of the PI3KCA
oncogene (p.H104R, p.E542K, p.E545K/D). The mutations
Table 1. Baseline characteristics of the patients.
No %
Age (median) 63 (36–87)
Male 84 61
Female 54 39
Performance Status
0 68 49
1 48 35
2 22 16
KRAS mutation status
Wild Type 88 64
Mutant Type 46 33
Undetermined 4 3
BRAF mutation status
Wild Type 123 89
Mutant Type 2 2
Undetermined 13 9
PI3KCA mutation status
Wild Type 105 76
Mutant Type 20 15
Undetermined 13 9
(N = 138).
doi:10.1371/journal.pone.0099886.t001
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p.H104R, p.E542K, p.E545K were detected with a sensitivity of
1% and p.E545D was detected with a sensitivity of 2%.
Extraction of RNA from PAXgene Blood RNA Tubes
Pretreatment blood samples were collected in PAXgene Blood
RNA tubes (Qiagen) and stored at 280uC according to the
manufactures instructions. Small RNAs were extracted from the
PAXgene Blood RNA tubes in two fractions.[18] These tubes
were processed on the BiorobotMDx (Qiagen, Hilden, Germany)
using a customized protocol that binds large RNAs and rescues the
run-through from the RNA binding plate. The binding condition
in the run-through was subsequently modified enabling the
miRNA to be purified on an RNeasy-96 plate. The concentration
of the small RNA fractions was assessed by absorbance spectrom-
etry on a DTX 880 (Beckman Coulter).
MiRNA Expression in Whole Blood
The miRNA profiling was performed on TaqMan Array
Human MicroRNA cards A and B v2.0 (Applied Biosystems)
using the manufactures reagents and instructions. RNA was
transcribed into cDNA in two multiplex reactions each containing
3 ml of the small RNA preparation and either Megaplex RT
Primer A Pool or Pool B pool and using the TaqMan MicroRNA
Reverse Transcription Kit in a total volume of 14 ml. Prior to
loading of the arrays a 12 cycle preamplification reaction was
performed using 2.5 ml cDNA in a 25 ml reaction. Each of the
arrays was loaded with 800 ml Universal PCR MasterMix assay
containing 1/40 of the preamplification reaction and run on the
7900 HT Fast Real-Time PCR System.
MiRNA Expression Analysis
Quality assessment. Samples with an absorbance below 1.8
were discarded and values with detection mean cycles greater than
29.5 were considered missing values. We calculated, to assess data
quality, the number of detected miRNAs per sample (Figure S1 in
file S1) and the mean miRNAs expression per sample (Figure S2 in
file S1). Internal controls were analyzed to assess reproducibility.
Normalization and filtering. Data were normalized by
using the Global Mean Normalization [19] and changes in the
expression were calculated using the 22DCt method. Data were
standardized before analysis.[20] Only the 138 samples with at
least 51% expressed miRNAs were retained. MiRNAs with more
than 21% (the cutoff is the estimated level at which the percentage
of retained miRNAs reaches a plateau) percent missing values
were discarded: 402 out of 768 were retained (372 miRNAs: only
part of them CRC specific and 30 control probes: replicates of U6,
RNU24, RNU43, RNU44, RNU48 and RNU6B).
Since the samples came from three different Hospitals, we
performed Principal Component Analysis to check for bias by
hospital. Figure S3 in file S1 shows some differences by center.
Data were adjusted by center using the batch-correction algorithm
ComBat, [21] from the Bioconductor library sva, [22] see Figure
S4 in file S1.
Statistical Analysis
Data were analyzed with R version 3.0.1. Mann-Whitney (if 2
groups) or Kruskal-Wallis (if more than 2 groups) tests followed by
P-values adjustment by the Benjamini & Hochberg method
(FDR,5%) were performed to determine differentially expressed
miRNAs between classes of samples (KRAS, BRAF, PI3KCA, double
wt, clinical benefit, performance status).
Univariable and multivariable survival analyses were performed
using the proportional hazards Cox regression (package ‘‘survival’’
in R). We reported single-test and Bonferroni-adjusted P-values
based on the number of miRNAs tested in the univariable overall
survival (OS) and progression free survival (PFS) regression
models. A bootstrap procedure (150 bootstraps as by default for
this procedure) from the regression modeling strategy was
performed to validate the fitted miRNAs based Cox survival
models (R library rms), concordance probabilities were calculated
by elaboration of the standard errors (among the other available
statistics) between the re-sampled fitted model and the original
model at every bootstrap step. The concordance measure
represents a probability, it measures how well our model
discriminates between different responses, where C= 0.5 implied
no predictive ability. In our case, C.0.5 means that that specific
miRNAs is a good predictor.
Multivariable survival analysis was performed with the following
variables: miRNAs (as continuous variables), gender, KRAS,
PI3KCA and age (dichotomized by median= 63 years). BRAF
was excluded from multivariable analysis due to the low number of
mutated patients with events (n = 2). The expressions of the
continuous miRNAs were dichotomized into High and Low risk
by the median of the expression values for visualization in the
Kaplan-Meier plots. Kaplan-Meier figures were reported for every
fitted survival model with at least one statistically significant
Figure 1. Kaplan-Meier curves showing the association between overall survival and pre-treatment miRNA expression in whole
blood from patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan. Patients were dichotomized by
the median expression value for miR-345. Low miRNA expression (red) and high miRNA expression (blue). The P-value refers to the Wald test.
doi:10.1371/journal.pone.0099886.g001
Table 2. List of prognostic miRNAs for overall survival. Hazard ratios with confidence intervals, Wald P-values and Bonferroni
adjusted P-values are given.
miRNA HR lower.95 upper.95 P-Wald P-Bonferroni
hsa-miR-345 2.377 1.804 3.132 7.70E-10 2.86E-07
hsa-miR-143 1.989 1.474 2.685 6.95E-06 2.59E-03
hsa-miR-34a* 1.787 1.349 2.369 5.27E-05 1.96E-02
hsa-miR-628-5p 1.693 1.307 2.195 6.84E-05 2.54E-02
hsa-miR-886-3p 1.582 1.255 1.993 1.01E-04 3.76E-02
hsa-miR-324-3p 0.551 0.428 0.71 4.17E-06 1.55E-03
doi:10.1371/journal.pone.0099886.t002
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miRNA. The Kaplan-Meier figures also show Hazard Ratios
(HR), confidence intervals (CI) and unadjusted Wald P-values
from Cox regression models for specific pairwise comparisons of
interest. Hazard ratios of continuous variables are presented in
interquartile range (IQR) units.
Target and Pathway Analysis
To identify molecular pathways potentially altered by the
expression of single or multiple miRNAs, we used the Diana-
mirPath software, [23] a web-based computational tool. The
software performs an enrichment analysis of the target genes of
multiple miRNAs by comparing them to all KEGG pathways.
The databases used were TarBase (www.microrna.gr/tarbase)
or microT-CDS (www.microrna.gr/microT-CDS).
Results
Clinical Characteristics and Mutation Status of the
Patients
After quality assessment, samples from five patients were
discarded. Baseline clinical characteristics and distribution of
KRAS, BRAF, and PI3KCA mutation status of the remaining 138
patients with mCRC included in the present biomarker study are
given in Table 1. All patients were treated without knowledge of
their mutational status.
miR-345 Was Prognostic for Overall Survival
One hundred and thirty two (95%) patients were dead at time of
follow-up (in September 2012). Median overall survival of the
patients was 10.6 months (95% CI: 2.1–38.2 months). No
difference in OS between the 3 centers was observed.
After adjusting with the Bonferroni method, we found six
prognostic miRNAs: high expression of miR-345, miR-143, miR-
34a*, miR-628-5p, miR-886-3p and low expression of miR-324-
Figure 2. Kaplan-Meier curves showing the association between overall survival and pre-treatment miR-345 expression in whole
blood from patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan. (A) Patients were dichotomized
by KRAS mutation status and miR-345. (B) Patients were dichotomized by BRAF wt mutations status and miR-345. (C) Patients were dichotomized by
PI3KCA mutation status and miR-345. (D) Patients were dichotomized by double wt mutation status and miR-345. The P-value refers to the Wald test.
doi:10.1371/journal.pone.0099886.g002
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3p were associated with short OS (Table 2). The Kaplan-Meier
plots for the six prognostic miRNAs are shown in Figure 1.
A full list of miRNAs prognostic for OS before Bonferroni
correction is provided in Table S1 in file S1;- a total of 64 miRNAs
out of 372 were prognostic, 50 with higher expression associated
with worse prognosis and 14 with lower expression associated to
worse prognosis, none of the controls (U6, RNU24, RNU43,
RNU44, RNU48 and RNU6B) were prognostic. A Volcano plot,
showing Z score as calculated by Cox regression analysis and an
unadjusted p value, is shown in Figure S5 in file S1.
Multivariable survival analysis was performed with the following
variables: miR-345, miR-143, miR-34a*, miR-628-5p, miR-886-
3p, miR-324-3p, gender, KRAS, PI3KCA and age (dichotomized by
median = 63 years). Results are reported in Table 3.
In OS, miR-345 and miR-324-3p were the only two miRNAs
that were statistically significant in both the multivariable analysis
and the univariable analysis. Performance status and KRAS were
also significant factors in the multivariable analysis, although KRAS
was borderline significant as a univariate factor (HR=1.36, CI
95%: 0.94–1.97).
miR-345 as a Single miRNA Marker for Clinical Outcome
miR-345 was also predictive for PFS, HR by IQR=1.7, (CI
95%: 1.31–2.2, adjusted Bonferroni P-value = 0.021). Besides
being significant for OS in the entire cohort, miR-345 was
statistically significant in all survival models for subgroups of
patients with wt of KRAS, BRAF, PI3KCA and double wt for the
combinations, KRAS+BRAF and KRAS+PI3KCA, see Tables S2–6
in file S1. miR-345 was prognostic for OS in the BRAF+PI3KCA wt
group and in the triple wt group (BRAF wt + KRAS wt + PI3KCA
wt) but not in the in the PFS analyses. We compared the available
mutational status in combination with the miR-345 expression
with regard to OS (Figure 2) and PFS (Figure 3).
The fitted Cox models were validated by resampling procedure.
The model fitted on miR-345 and OS showed good concordance,
higher than every other analyzed miRNAs in OS (Figure S6 in file
S1).
We also checked whether miR-345 expression was associated
with response to treatment and clinical benefit. We could see that
higher expression was associated with lack of response (Figure 4).
To analyze this further, we restricted our set of patients to those
with a partial response (n = 24) and progressive disease (n = 37) in
Figure 3. Kaplan-Meier curves showing the association between progression free survival, pre-treatment miR-345 expression in
whole blood and mutational status of patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan.
Patients were dichotomized by low miR-345 expression (red) and high miR-345 expression (blue). (A) Patients were dichotomized by the median
expression value for miR-345. (B) Patients were dichotomized by KRAS mutations status and miR-345. (C) Patients were dichotomized by BRAF WT
mutations status and miR-345. (D) Patients were dichotomized by PI3KCA mutations status and miR-345. (E) Patients were dichotomized by double
wt mutation status and miR-345. The P-value refers to the Wald test.
doi:10.1371/journal.pone.0099886.g003
Figure 4. Box plot showing the association between miR-345 expression and response to treatment (partial response, stable
disease and progression). Mann-Whitney test; KRAS wt patients (green dots), KRASmutated patients (red dots). If we restrict our set of
patients to those with partial response (n = 24) and progressive disease (n = 37), a significant relationship between miR-345 expression and response
to therapy was obtained with an odds ratio of 5.37, (P-value = 0.004 and 95% CI: 1.56–20.94).
doi:10.1371/journal.pone.0099886.g004
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best overall response. We then compared the number of patients
with a lower and higher miR-345 expression according to the
median expression of miR-345 and obtained a significant
relationship between miR-345 expression and response to therapy
with an odds ratio of 5.37 (P-value= 0.004; 95% CI: 1.56–20.94).
Pathway and Target Analysis
To identify molecular pathways associated to the expression of
the six miRNAs prognostic for OS (miR-345, miR-143, miR-34a*,
miR-628-5p, miR-886-3p, miR-324-3p), we tested KEGG path-
ways. Among the statistically significant ones, colorectal cancer
(KEGG pathway hsa05210) was present due to the predicted
interactions between these miRNAs and the following target
genes: TCF4, APC, SMAD4, MAPK8, PIK3CG, PIK3CD,
DCC, PIK3CG, PIK3CA and MAPK1.
Discussion
In first and later lines of treatment of patients with mCRC the
addition of cetuximab to chemotherapy may be beneficial in
patients without mutations in KRAS and BRAF [24,25,26].
However, recent studies investigating cetuximab in first line
mCRC, could not confirm a benefit in PFS and OS in KRAS wt
patients.[27,28]. There is a need for more precise biomarkers or
panels of biomarkers. The present prospective biomarker study
was conducted to identify prognostic miRNAs in whole blood
from patients with mCRC treated with 3rd line cetuximab and
irinotecan.
Our study suggests a potential role of circulating miRNAs to
serve as biomarkers for clinical outcome in patients with mCRC.
We found that miR-345 was prognostic for OS in all our patients
with mCRC and in the KRAS wt patients, with high expression
associated with shorter survival. Multivariable analysis demon-
strated that miR-345 was a strong factor that added prognostic
information to the other available clinicopathologic and mutation
variables. Tumor burden is a combination of tumor size and
number of metastatic sites. Data regarding tumor size was not
available to us, and therefore tumor burden could not be included
in the multivariable analysis. We did, however, include a
representative list of covariates which are regarded as prognostic
factors for patients with mCRC treated with cetuximab.
miR-345 was statistically significant for all wt subgroups
analyzed. Since all patients were treated with cetuximab, we
cannot deduce whether miR-345 was a prognostic biomarker
(independent of treatment the patients received) or a biomarker
predicting sensitivity to treatment with cetuximab and irinotecan,
but we found that its higher expression was associated with lack of
response to therapy. In the isolated group of responders versus
non-responders, a high miR-345 expression was significantly
associated with a 5 times risk of progressive disease as best overall
response. These results are novel findings and suggest that this
miRNA is prognostic and may be a potential biomarker for
response in patients with mCRC treated with cetuximab and
irinotecan.
Circulating miR-345 has to our knowledge, not previously been
described in connection with CRC, but Tang and colleagues
reported that a low level of miR-345 in CRC tissue is associated
with lymph node metastases, worse histological type and is up-
regulated in colorectal cancer cell lines after treatment with 5-aza-
dc [29]. In addition, DNA-methylation levels in the promoter
region of miR-345 are higher in CRC tissue compared to normal
colon tissue and corresponding non-cancerous tissue, suggesting
that this miRNA is a methylation sensitive tumor suppressor [29].
In tissue samples, miR-345 is prognostic in patients with breast
cancer [30]. Although validation in external cohorts was not
statistically significant, miR-345 was the only miRNA to remain
prognostic in a multivariable model, accounting for key clinical
parameters [30].
It is not known why there is a discrepancy between miRNA
expression in tissue and blood from patients with CRC. Few
studies have compared miRNA expression in corresponding tissue
and blood samples. Little overlap is seen between miRNAs
differentiating lung cancer samples from normal lung tissue
samples and plasma miRNAs differentiating patients with
aggressive vs. non-aggressive lung cancer.[31] miR-345 was found
decreased in CRC tissue in a relatively small study of 26 CRC
tissue samples in which only 5 patients had metastatic disease. [29]
A low miR-345 concentration in predominantly localized CRC
tissue may not be comparable to high concentration of circulating
miR-345 in metastatic CRC. The same miRNA may be tumor-
related in different ways, depending on, if it is found in the tumor
or as a circulating miRNA.
miR-143 is down- regulated in CRC tumor samples as
compared to normal tissue.[32,33,34] KRAS may be a target for
miR-143[35] and levels of miR-143 expression in CRC tumour
samples are a prognostic biomarker in KRAS wt patients but not a
predictive marker for anti-EGFR treatment.[36] Circulating miR-
143 has been tested as diagnostic marker in CRC patients, but is
not significantly deregulated compared to normal controls.[37]
miR-324-3p has not been described in CRC, but is differently
expressed in plasma from patients with breast cancer compared to
healthy controls.[38].
The strength of our study was the relatively large sample size,
bootstrap procedure (resampling validation of the Cox regression
model), and a strict statistical approach using only miRNAs
adjusted in accordance with the Bonferroni correction. The next
step will be to validate these significant miRNAs in whole blood
from another cohort of patients with mCRC treated with
cetuximab and irinotecan. At present no such samples are
available from completed phase III studies.
No studies have investigated whether miRNA expressions in
whole blood have a potential as prognostic or predictive
biomarkers in patients with mCRC treated with cetuximab and
irinotecan. Most studies investigating circulating miRNAs have
used plasma or serum.[39,40] miRNA expression profiles in whole
blood collected in PAXgene RNA tubes have been described in
patients with hematologic diseases, pancreatic and lung cancer
[41,42] and have advantages compared to miRNA in serum/
plasma due to higher yield [43] of miRNAs and fewer
methodological problems [44]. MiRNAs found in peripheral
whole blood can originate from cancer cells but also from non-
cancerous cell such as leucocytes, thrombocytes and monocytes.
They can be in the blood stream bound to proteins like AGO [45]
and HDL [46] or packed in exosomes.[47] The prognostic
miRNAs, found in our group of patients, may be due to tumor
progression, an inflammatory response or as a response to organ
failure.
Recently, Shen and colleagues reported, that EGFR was
involved in the suppression of specific miRNA maturation in
response to hypoxic stress.[48] The proposed mechanism was that
an EGFR through phosphorylation of AGO2, caused a reduction
of DICER/AGO2 binding [48] hereby inhibiting the maturation
of pre-miRNAs with long-loop configuration. Inhibition of EGFR
may also cause intracellular miRNA regulation and transport
some of the altered miRNAs into the blood stream, thereby acting
as a circulating response to EGFR actions.
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Conclusion
We identified six circulating miRNAs in whole blood as
prognostic markers for OS. miR-345 was a single biomarker for
OS in all patients and in subgroups of patients with KRAS wt and
KRAS+BRAF double wt. Furthermore, miR-345 was significantly
associated with PFS and best overall response and may be a
potential biomarker for clinical outcome in patient with mCRC
treated with 3rd line cetuximab and irinotecan.
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